Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Entera reports robust data for pipeline programs in HypoPT and obesity

Entera Bio (NASDAQ: ENTX) has reported preclinical data at ENDO 2026, the annual meeting of the Endocrine Society, for its pipeline programs—EB612 in hypoparathyroidism (HypoPT) and EB618 in obesity and metabolic...

June 16, 2026

Developments

Faron unveils immunotherapy data in myeloid malignancies at EHA

Faron Pharmaceuticals (AIM: FARN; First North: FARON) announced a poster presentation highlighting biological evidence from the BEXMAB Phase 1/2 trial validating its first-in-class immunotherapy candidate, bexmarilimab...

June 15, 2026

Developments

Context reports positive data for CTIM-76 in PROC

Context Therapeutics (NASDAQ: CNTX) has announced positive interim Phase 1 clinical data for its CLDN6 x CD3 T cell engaging bispecific antibody, CTIM-76, in advanced, late-line platinum-resistant ovarian cancer (PROC)...

June 15, 2026

Developments

Evaxion presents new data for off-the-shelf AML vaccine

Evaxion (NASDAQ: EVAX) has announced new preclinical data for EVX-04, an AI-designed off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML) that targets multiple endogenous retrovirus (ERV) tumor antigens...

June 11, 2026

Developments

60 Degrees signs licensing agreement with Florida State for botanical supplement

60 Degrees Pharmaceuticals (NASDAQ: SXTP; SXTPW) has announced that it has executed a patent licensing agreement with Florida State University to commence large-scale production techniques to extract and purify...

June 11, 2026

Developments

Caribou reports long-term vispa-cel data in r/r B-NHL

Caribou Biosciences (NASDAQ: CRBU) has announced that vispa-cel, its off-the-shelf CD19-targeted CAR-T cell therapy, produced durable long-term responses in patients enrolled in the ANTLER phase 1 clinical trial for...

June 11, 2026

Developments

Valion confirms HASC initiative to address urgent need for radiation/nuclear countermeasures

Valion Bio (NASDAQ: VBIO) confirmed that the U.S. House Armed Services Committee‘s FY27 National Defense Authorization Act report directs the Assistant Secretary of Defense for Nuclear Deterrence, Chemical, and...

June 11, 2026

Developments

Cantargia reports launch of investigator-led lung cancer prevention study

Cantargia (STO: CANTA) has announced that the first patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current or previous smokers with multifocal high-risk lung nodules, and at...

June 10, 2026

Developments

Sensorion selects SENS-601 for hearing loss as lead program; files for trials in Canada and France

Sensorion (EPA: ALSEN) announced the selection of SENS-601 which addresses GJB2-related hearing loss as its lead program. A clinical trial application has been filed in Canada and France to evaluate the safety...

June 10, 2026

Developments

Cullinan shares data from T cell engager programs targeting autoimmune diseases

Cullinan Therapeutics (NASDAQ: CGEM) has reported clinical data and outlined global clinical development plans for CLN-978, a CD19xCD3 T cell engager, and velinotamig, a BCMAxCD3 T cell engager, in autoimmune diseases...

June 10, 2026

Developments

INOVATE selects Perimeter for contribution to advance AI for breast cancer surgery

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced it has been selected to receive a contribution from the INOVAIT Pilot Fund to advance next-generation AI capabilities for its flagship product...

June 9, 2026

Developments

FDA clears Pentixapharm IND for cardiovascular diagnostic program

Pentixapharm Holding (Frankfurt Prime Standard: PTP) has announced that the FDA has cleared its Investigational New Drug (IND) application for its lead CXCR4-targeted diagnostic program in treatment resistant...

June 9, 2026

Developments

ZEO adds nine experts in regenerative and longevity medicine to advisory board

ZEO ScientifiX (OTCQB: ZEOX) has announced the expansion of its medical advisory board with the addition of nine physicians and scientific innovators across key disciplines in regenerative and longevity medicine. The...

June 9, 2026

Developments

Eledon reports insulin independence in islet transplant patients treated with tegoprubart

Eledon Pharmaceuticals (NASDAQ: ELDN) announced updated results from an investigator-initiated trial evaluating tegoprubart, its investigational anti-CD40L antibody, as part of a calcineurin inhibitor-free...

June 8, 2026

Developments

Seaport reports positive dose data from trial of GlyphAgo for anxiety

Seaport Therapeutics (NASDAQ: SPTX) has announced positive data from the multiple-ascending dose portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo (SPT-320), a novel, Glyphed...

June 8, 2026

Developments

Shattuck announces Phase 1 results for SL-325 antibody

Shattuck Labs (NASDAQ: STTK) has announced data from its Phase 1 trial evaluating the safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamics, and immunogenicity of SL-325, its lead DR3 blocking...

June 8, 2026

Developments

ANSM grants clearance for Anteris trial of transcatheter heart valve

Anteris Technologies Global (NASDAQ: AVR; ASX: AVR) has received full regulatory clearance from the French National Agency for Medicines and Health Products Safety (ANSM) enabling patient recruitment to begin in France...

June 8, 2026

Developments

MindBio launches AI software for drug use and fatigue detection

MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) has launched its lead commercial software Intox AI for validation and testing of intoxication and fatigue. Intox AI enables new analytical capabilities to...

June 5, 2026

Developments

TelyRx commences trading on OTCQX

TelyRx Holdings (TSX: TELY; OTCQX: TELYF) has announced that its subordinate voting shares will commence trading on the OTCQX Best Market (OTCQX), the premier tier of the OTC Markets Group in the U.S., under the symbol...

June 5, 2026

Developments

Profound Medical’s TULSA procedure highlighted on popular podcast, Over 50 & Flourishing

In a recent two-part Over 50 & Flourishing video and podcast, host Dominique Sachse sat down with her husband, voice actor and singer Vic Mignogna, to discuss his health journey, including a diagnosis of prostate...

June 4, 2026

Developments

VolitionRx files patent for Ebola triage and treatment monitoring test

VolitionRx (NYSE AMERICAN: VNRX) has announced the filing of a strategic patent application covering the use of its proprietary Nu.Q technology in triaging and monitoring patients who are suspected of having contracted...

June 3, 2026

Developments

AACN journal publishes study showing benefits of ENvue’s feeding tube guidance platform

ENvue Medical (NASDAQ: FEED) has announced that Critical Care Nurse, the official journal of the American Association of Critical-Care Nurses (AACN), has published an independent, peer-reviewed study showing significant...

June 3, 2026

Subscribe